Sorry, you need to enable JavaScript to visit this website.
connect-patient icn_chatbot_expand_mf

Connect With
a Patient
Like Sue


Connect With a
Patient Like Sue

Register for the Incyte Mentor Program and connect with another patient taking Jakafi.

Email Address

Continue Registering 


Patient Stories

Hear from real patients taking Jakafi® (ruxolitinib) and their loved ones. If you have intermediate- or high-risk myelofibrosis (MF), you’re not alone.

Nick’s Story

Nick was diagnosed with high-risk MF after a routine medical check. Hear Nick discuss his experience with MF symptoms, as well as some of the challenges he faces living with MF.

Sue’s Story

A devoted wife and mother, Sue was surprised when a diagnosis of intermediate-risk MF made her miss out on plans to see her oldest son play college baseball. Watch Sue's story and learn about her journey with intermediate-risk MF.

IncyteCARES Patient Experiences

Hear how the patient support program, IncyteCARES, has helped eligible patients with information and support for the treatment journey with Jakafi.

Sue’s IncyteCARES Story

Hear Sue share how IncyteCARES—a patient support program for eligible adults taking Jakafi—connected her with information regarding coverage and educational support to help her throughout her journey with Jakafi.

Rob’s IncyteCARES Story

IncyteCARES gave Rob additional support to help move his treatment journey forward. Learn more about this patient support program for eligible adults taking Jakafi.

Professional Perspectives

Hear from a medical professional who specializes in myeloproliferative neoplasms including myelofibrosis. When it comes to learning about your condition, it can be helpful to listen to real myeloproliferative neoplasm (MPN) experts who treat these rare, chronic blood cancers every day. The following videos have been developed to help you learn more about your myelofibrosis and discover what may be possible with Jakafi.

Jakafi: a Targeted Therapy

Discover how Jakafi works to reduce overactive JAK signaling.

What Effects Has Jakafi Shown in Clinical Trials?

Learn about the results of two clinical studies that explored whether Jakafi® (ruxolitinib) reduced enlarged spleens in certain patients.

What Long-Term Data Are Available for Jakafi?

Learn more about the results of two clinical studies for Jakafi that researched spleen size and analyzed overall survival in certain types of MF.

How Can Certain Risk Factors Help Me Understand My Myelofibrosis?

Explore 8 risk factors that Healthcare Professionals use to determine the severity of myelofibrosis (MF) in patients.

How Do I Take Jakafi?

Find out how patients can work with their Healthcare Professional to ensure they are prescribed the dose of Jakafi that is appropriate for their particular circumstances.

Is Jakafi Long-Term Treatment?

Learn about the patients and conditions Jakafi is used to treat.

What Are the Common Side Effects of Jakafi?

Explore the most common side effects of Jakafi and learn what patients should report to their Healthcare Professional.

Educational Videos

Learn more about myelofibrosis with an educational video designed to support your treatment journey with Jakafi.

Myelofibrosis, Spleen Size & You 

Learn why spleen size is an important health focus in MF and how patients can partner with their Healthcare Professionals to help identify and monitor the signs and symptoms of spleen enlargement in MF.







Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi is used to treat adults with certain types of myelofibrosis.

Jakafi is used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough.

Jakafi is also used to treat adults and children 12 years of age and older with chronic GVHD who have taken one or two types of treatments and they did not work well enough.

Important Safety Information

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi® (ruxolitinib) may cause low platelet, red blood cell, and white blood cell counts. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will do a blood test to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Cancer: Some people have had certain types of non-melanoma skin cancers during treatment with Jakafi. Your healthcare provider will regularly check your skin during your treatment with Jakafi. Tell your healthcare provider if you develop any new or changing skin lesions during treatment with Jakafi.

Increases in cholesterol: You may have changes in your blood cholesterol levels during treatment with Jakafi. Your healthcare provider will do blood tests to check your cholesterol levels about every 8 to 12 weeks after you start taking Jakafi, and as needed.

Increased risk of major cardiovascular events such as heart attack, stroke or death in people who have cardiovascular risk factors and who are current or past smokers while using another JAK inhibitor to treat rheumatoid arthritis: Get emergency help right away if you have any symptoms of a heart attack or stroke while taking Jakafi, including: discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back, severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw, pain or discomfort in your arms, back, neck, jaw, or stomach, shortness of breath with or without chest discomfort, breaking out in a cold sweat, nausea or vomiting, feeling lightheaded, weakness in one part or on one side of your body, slurred speech.

Increased risk of blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) have happened in people taking another JAK inhibitor for rheumatoid arthritis and may be life-threatening. Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with Jakafi, including: swelling, pain, or tenderness in one or both legs, sudden, unexplained chest or upper back pain, shortness of breath or difficulty breathing.

Possible increased risk of new (secondary) cancers: People who take another JAK inhibitor for rheumatoid arthritis have an increased risk of new (secondary) cancers, including lymphoma and other cancers. People who smoke or who smoked in the past have an added risk of new cancers.

The most common side effects of Jakafi include: for certain types of myelofibrosis (MF) and polycythemia vera (PV) – low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea; for acute GVHD – low platelet counts, low red or white blood cell counts, infections, and swelling; and for chronic GVHD – low red blood cell or platelet counts and infections including viral infections.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Call your doctor for medical advice about side effects.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had low white or red blood cell counts, have or had tuberculosis (TB) or have been in close contact with someone who has TB, had shingles (herpes zoster), have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had cancer, are a current or past smoker, had a blood clot, heart attack, other heart problems or stroke, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.

Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.

Please see the Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.